Amarin Corporation PLC
500 articles about Amarin Corporation PLC
-
Amarin Corporation PLC Announces U.S. Patent 8,298,554 Issuance for Vascepa
10/30/2012
-
Will AstraZeneca PLC Bid for Amarin Corporation PLC? Rumors Swirl
10/24/2012
-
Amarin Corporation PLC Announces Issuance of U.S. Patents 8,793,727 and 8,293,728 for Vascepa
10/23/2012
-
Amarin Corporation PLC Still Awaits FDA OK for Heart Drug
9/11/2012
-
Amarin Corporation PLC Announces Notification of Patent Allowance for U.S. Application 13/349,150 Related to Vascepa and FDA Approved MARINE Indication
9/10/2012
-
Amarin Corporation PLC Announces Notification of Patent Allowance for U.S. Application 13/284,408 Related to Vascepa and FDA Approved MARINE Indication
9/6/2012
-
Amarin Corporation PLC Announces Notification of Patent Allowances for U.S. Applications 12/702,889 and 13/349,153 Related to Vascepa and FDA Approved MARINE Indication
9/5/2012
-
Amarin Corporation PLC Announces Notification of Patent Allowance for U.S. Application 13/282,145 Related to Vascepa and FDA Approved MARINE Indication
9/4/2012
-
Amarin Corporation PLC Announces Additional Publication of MARINE Phase 3 Clinical Trial Results in the Journal of Clinical Lipidology
8/29/2012
-
Amarin Corporation PLC Reports Second Quarter 2012 Financial Results and Provides Update on Operations
8/9/2012
-
Is Amarin Corporation PLC GlaxoSmithKline's New Target?
8/2/2012
-
Amarin Corporation PLC to Report Second Quarter 2012 Financial Results and Host Conference Call on August 8, 2012
7/31/2012
-
Amarin Corporation PLC's Fish Oil Drug Wins FDA Approval to Treat High Blood Fats
7/30/2012
-
Amarin Corporation PLC FDA Approval Likely Today
7/27/2012
-
Amarin Corporation PLC Receives Notice of Intention to Grant on European Patent
7/25/2012
-
Amarin Corporation PLC Announces Publication of ANCHOR Phase 3 Clinical Trial Results in The American Journal of Cardiology
7/24/2012
-
Website Goof on False Heart Drug Approval Gives Amarin Corporation PLC a Boost
7/23/2012
-
Amarin Corporation PLC Announces Notice of Allowance for Additional U.S. Patent Covering AMR101
7/2/2012
-
Amarin Corporation PLC Release: AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus (Type 2) to be Presented at the American Diabetes Association's 72nd Scientific Sessions
6/4/2012
-
Amarin Corporation PLC to Present at the Jefferies and Co. 2012 Global Healthcare Conference
5/30/2012